← Patent-cliff monitor small molecule ELUCIREM GADOPICLENOL
Loss of exclusivity January 2040 latest FDA-listed patent expiry
Company Guerbet → See this company's full patent-cliff portfolio Drug detail Brand name ELUCIREM Active ingredient GADOPICLENOL Strength 48.51GM/100ML (485.1MG/ML) Dosage form SOLUTION Route INTRAVENOUS Modality Small molecule FDA approval September 2022 Marketing status RX
Listed patents Patent Expires Type 11590246 January 2040 product 10973934 August 2039 substance 8114863 May 2032 substance, product
Regulatory exclusivity Code Expires NPP February 2029 NCE September 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.